Development of Bacteriocins into Therapeutic Formulation.

By: Physician's Weekly Admin

Posted on: December 15, 2020

Development of Bacteriocins into Therapeutic Formulation.

One of the pathogens is methicillin-resistant Staphylococcus aureus (MRSA), which is a major cause of skin and soft tissue infections.In clinical settings, the bacterium is the leading cause of endocarditis, bacteremia, and chronic osteomyelitis. Bacteriocins are ribosomally incorporated antimicrobial peptides that are commonly steady over broad ranges of temperature and pH, with low toxicity and high antimicrobial action at  therapeutically acceptable concentrations. In this examination, we investigated the capability of two broad range bacteriocins, garvicin KS and micrococcin P1, in skin disease medicines. The rise of anti-infection resistant microorganisms has caused a genuine problem throughout the globe in disease treatment. The current treatment regimen for patients hospitalized with MRSA-associated SSTIs includes vancomycin, linezolid, daptomycin, or ceftaroline. The MICs of the antimicrobials in the three-component mixture were 40 ng/ml for micrococcin P1 and 2 μg/ml for garvicin KS and penicillin G, which were 62, 16, and at least 1,250 times lower than their MICs when assessed individually. As a result,it was evident that,  the three-component formulation was efficient in eradicating the pathogen from treated wounds.

Reference link- https://aac.asm.org/content/64/12/e00829-20